In the other three studies with MET inhibitors in patients with METex14 skipping NSCLC, the most common TRAEs were: peripheral edema, nausea, vomiting, and increased blood creatinine (GEOMETRY mono-1, capmatinib); peripheral edema, nausea, increased ALT, increased AST, and increased blood creatinine (savolitinib study in Chinese patients); and edema, hypoalbuminemia, headache, loss of appetite, nausea, increased blood bilirubin, increased ALT, vomiting, and increased AST (GLORY, gumarontinib) [22, 23, 30]. Here, GPT is linked to Hypoalbuminemia.